Kunnathur Murugesan Sakthivel

Kunnathur Murugesan Sakthivel

Auto-generated profile, based on publicly available information

Kunnathur Murugesan Sakthivel

Department of Biochemistry, PSG College of Arts & Science, Civil Aerodrome Post, Coimbatore, India

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in International Immunopharmacology
Verified
Journal Article
Closed access
KSK.M. Sakthivel
K.M. Sakthivel
CGC. Guruvayoorappan
C. Guruvayoorappan

28 November 2022 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
LDLoganathan Chandramani Priya Dharshini
Loganathan Chandramani Priya Dharshini
RRRajan Radha Rasmi
Rajan Radha Rasmi
CKChinnadurai Kathirvelan
Chinnadurai Kathirvelan
KKKalavathi Murugan Kumar
Kalavathi Murugan Kumar
KSK. M. Saradhadevi
K. M. Saradhadevi
KSKunnathur Murugesan Sakthivel
Kunnathur Murugesan Sakthivel

14 November 2016 in Oncology Reviews
Verified
Journal Article
Open access
PDF file
KSKunnathur Murugesan Sakthivel
Kunnathur Murugesan Sakthivel
PSPoonam Sehgal
Poonam Sehgal
Lamins are the key components of the nuclear lamina and by virtue of their interactions with chromatin and binding partners act as regulators of cell proliferation and differentiation. Of late, the diverse roles of lamins in cellular processes have made them the topic of intense debate for their role in cancer progression. The observations about aberrant localization or misexpression of the nuclear lamins in cancerous tissues have often led to the speculative role of lamins as a cancer risk biomarker. Here we discuss the involvement of lamins in several cancer subtypes and their potential role in predicting the tumor progression.

31 August 2012 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
KSK.M. Sakthive
K.M. Sakthive
NKN. Kannan
N. Kannan
AAA. Angeline
A. Angeline
CGC. Guruvayoorappan
C. Guruvayoorappan
The aim of the present investigation was to evaluate the effect of A. nilotica extract against Dalton's ascitic lymphoma (DAL) induced solid and ascitic tumors in BALB/c mice. Experimental animals received A. nilotica extract (10 mg/kg.bw) intraperitoneally for 10 and 14 consecutive days before induction of solid and ascitic tumors, respectively. Treatment with A. nilotica extract significantly decreased the development of tumor and percentage increase in body weight when compared to DAL induced solid tumor control group, also increasing the life span, restoring the total white blood cell count and hemoglobin content and significantly decreasing the levels of serum aspartate transaminase (SGPT), alanine transaminase (SGOT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT) and nitric oxide (NO) when compared to DAL induced ascitic tumor controls. The treatment also reduced significantly the cellular glutathione (GSH) and nitric oxide levels in treated animals. Histopathological studies also confirmed protective influence. The outcome of the present work indicates that A. nilotica extract could be used as natural anticancer agent for human health.

30 June 2013 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
KSKunnathur Murugesan Sakthivel
Kunnathur Murugesan Sakthivel
CGChandrasekaran Guruvayoorappan
Chandrasekaran Guruvayoorappan
The aim of the present investigation was to evaluate the effect of A ferruginea extract on Dalton's lymphoma ascites (DLA) induced tumours in BALB/c mice. Experimental animals received A ferruginea extract (10 mg/ kg.b.wt) intraperitoneally for 14 consecutive days after DLA tumor challenge. Treatment with extract significantly increased the life span, total white blood cell (WBC) count and haemoglobin (Hb) content and decreased the level of serum aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (γ-GT) and nitric oxide (NO) in DLA bearing ascites tumor models. In addition, administration of extract significantly decreased the tumour volume and body weight in a DLA bearing solid tumor model. The levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6) and granulocyte monocyte-colony stimulating factor (GM-CSF), as well as pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase (iNOS) were elevated in solid tumour controls, but significantly reduced by A ferruginea administration. On the other hand, the extract stimulated the production of interleukin-2 (IL-2) and interferon-gamma (IFN-γ) in animals with DLA induced solid tumours. Increase in CD4+ T-cell population suggested strong immunostimulant activity for this extract. GC/MS and LC/MS analysis showed quinone, quinoline, imidazolidine, pyrrolidine, cyclopentenone, thiazole, pyrazole, catechin and coumarin derivatives as major compounds present in the A ferruginea methanolic extract. Thus, the outcome of the present study suggests that A ferruginea extract has immunomodulatory and tumor inhibitory activities and has the potential to be developed as a natural anticancer agent.

1 January 2014 in Journal of Environmental Pathology, Toxicology and Oncology
Verified
Journal Article
Closed access
KSKunnathur Murugesan Sakthivel
Kunnathur Murugesan Sakthivel
GCGuruvayoorappan Chandrasekaran
Guruvayoorappan Chandrasekaran
In the present study, we evaluated the protective effect of A. ferruginea extract against ulcerative colitis (UC). Male Wistar rats received A. ferruginea extract (10 mg/kg body weight) or sulfasalazine (100 mg/kg body weight) for 5 consecutive days before inducing UC via intrarectal acetic acid (3%) administration. Colonic mucosal injury was assessed by macroscopic scoring, vascular permeability testing, and histopathological examination. The mucosal contents of glutathione, lipid peroxidation, superoxide dismutase, and nitric oxide were evaluated as parameters for the redox state. Inflammatory response was determined by measuring inducible nitric oxide synthase (iNOS) and cyclo-oxygenase (COX-2) expression. Myeloperoxidase (MPO), lactate dehydrogenase assay (LDH), tumor necrosis factor (TNF-α), and interleukins (IL-1β and IL-6) were measured using ELISA. Transcription factor profiling of nuclear factor (NF)-κB subunits (p65/p50) was also conducted using ELISA. All of the relevant parameters were altered in rats with UC, and these parameters improved in animals that received A. ferruginea extract. Colonic mucosal injury parallels antioxidant and anti-inflammatory evaluations, and A. ferruginea extract was considered comparable to the standard treatment drug sulfasalazine. Histopathological studies confirmed these findings. A. ferruginea extract inhibited the activation and translocation of transcription factors, that is, NF-κB subunits (p65/p50). The results of our investigation clearly indicate that treatment with A. ferruginea extract exerted a marked protective effect against experimental UC via modulation of oxidant/anti-oxidant balance and inhibition of inflammatory mediators.